Lung cancer screening: the way forward
- PMID: 18665179
- PMCID: PMC2527832
- DOI: 10.1038/sj.bjc.6604509
Lung cancer screening: the way forward
Abstract
To take lung cancer screening into national programmes, we first have to answer the question whether low-dose computed tomography (LDCT) screening and treatment of early lesions will decrease lung cancer mortality compared with a control group, to accurately estimate the balance of benefits and harms, and to determine the cost-effectiveness of the intervention.
References
-
- Bach PB, Jett JR, Pastorino U, Tockman MS, Swensen SJ, Begg CB (2007) Computed tomography screening and lung cancer outcomes. JAMA 297: 953–961 - PubMed
-
- Bach PB, Kattan MW, Thornquist MD, Kris MG, Tate RC, Barnett MJ, Hsieh LJ, Begg CB (2003) Variations in lung cancer risk among smokers. J Natl Cancer Inst 95: 470–478 - PubMed
-
- Black C, Bagust A, Boland A, Walker S, McLeod C, De Verteuil R, Ayres J, Bain L, Thomas S, Godden D, Waugh N (2006) The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer: systematic reviews. Health Technol Assess 10(3): iii–iv, ix–x, 1–90 - PubMed
-
- Blanchon T, Brechot JM, Grenier PA, Ferretti GR, Lemarie E, Milleron B, Chague D, Laurent F, Martinet Y, Beigelman-Aubry C, Blanchon F, Revel MP, Friard S, Remy-Jardin M, Vasile M, Santelmo N, Lecalier A, Lefebure P, Moro-Sibilot D, Breton JL, Carette MF, Brambilla C, Fournel F, Kieffer A, Frija G, Flahault A (2007) Baseline results of the Depiscan study: a French randomized pilot trial of lung cancer screening comparing low dose CT scan (LDCT) and chest X-ray (CXR). Lung Cancer 58: 50–58 - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
